Intellia Therapeutics (NTLA) Net Cash Flow (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Net Cash Flow data on file, last reported at -$17.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$17.5 million, up 68.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 105.12% YoY), and the FY2025 annual result was -$35.2 million, up 6.25% from the prior year.
• Net Cash Flow improved to -$17.5 million in Q1 2026 per NTLA's latest filing, from -$39.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $385.7 million in Q4 2022 and troughed at -$229.4 million in Q1 2023.
• A 5-year average of $1.4 million and a median of -$6.9 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 1629.85% in 2023, then jumped 459.45% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $385.7 million in 2022, then slumped by 84.61% to $59.4 million in 2023, then increased by 15.7% to $68.7 million in 2024, then tumbled by 157.91% to -$39.8 million in 2025, then jumped by 56.08% to -$17.5 million in 2026.
• Business Quant data shows NTLA's Net Cash Flow at -$17.5 million in Q1 2026, -$39.8 million in Q4 2025, and $37.2 million in Q3 2025.